While there are infiltrative gliomas with MAPK pathway activation that may demonstrate progression over time, or have a first presentation with high-grade histology, these tumors usually have MAPK pathway activation through structural alterations in FGFR or NTRK family genes, or have pathogenic variants of NF1 or BRAF [17–22]. Here, BRAF is linked to central nervous system cancer.